Equities research analysts at StockNews.com assumed coverage on shares of Merrimack Pharmaceuticals (NASDAQ:MACK – Get Rating) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Shares of NASDAQ:MACK opened at $5.93 on Wednesday. Merrimack Pharmaceuticals has a 52 week low of $3.66 and a 52 week high of $7.41. The company’s fifty day moving average is $5.48 and its 200-day moving average is $5.42. The company has a market capitalization of $79.52 million, a PE ratio of -42.35 and a beta of 1.69.
Merrimack Pharmaceuticals (NASDAQ:MACK – Get Rating) last issued its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.04) EPS for the quarter.
Large investors have recently made changes to their positions in the business. Radnor Capital Management LLC bought a new stake in Merrimack Pharmaceuticals during the 4th quarter worth about $52,000. Yakira Capital Management Inc. raised its holdings in Merrimack Pharmaceuticals by 21.1% during the 4th quarter. Yakira Capital Management Inc. now owns 73,450 shares of the biopharmaceutical company’s stock worth $287,000 after purchasing an additional 12,816 shares during the last quarter. BlackRock Inc. raised its holdings in Merrimack Pharmaceuticals by 12.8% during the 3rd quarter. BlackRock Inc. now owns 211,051 shares of the biopharmaceutical company’s stock worth $1,020,000 after purchasing an additional 23,961 shares during the last quarter. Sepio Capital LP raised its holdings in Merrimack Pharmaceuticals by 276.2% during the 1st quarter. Sepio Capital LP now owns 296,546 shares of the biopharmaceutical company’s stock worth $1,876,000 after purchasing an additional 217,717 shares during the last quarter. Finally, Bronte Capital Management Pty Ltd. raised its holdings in Merrimack Pharmaceuticals by 7.6% during the 1st quarter. Bronte Capital Management Pty Ltd. now owns 578,313 shares of the biopharmaceutical company’s stock worth $3,658,000 after purchasing an additional 40,729 shares during the last quarter. 55.93% of the stock is owned by hedge funds and other institutional investors.
About Merrimack Pharmaceuticals (Get Rating)
Merrimack Pharmaceuticals, Inc operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Featured Articles
- Get a free copy of the StockNews.com research report on Merrimack Pharmaceuticals (MACK)
- Are These Cheap Copper Stocks Right For Your Portfolio?
- Zai Lab Stock Has Fallen to Value Levels
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.